220 related articles for article (PubMed ID: 32543760)
1. Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity interactions.
Bermejo-Pareja F; Del Ser T; Valentí M; de la Fuente M; Bartolome F; Carro E
Alzheimers Dement; 2020 Aug; 16(8):1196-1204. PubMed ID: 32543760
[TBL] [Abstract][Full Text] [Related]
2. Decreased salivary lactoferrin levels are specific to Alzheimer's disease.
González-Sánchez M; Bartolome F; Antequera D; Puertas-Martín V; González P; Gómez-Grande A; Llamas-Velasco S; Herrero-San Martín A; Pérez-Martínez D; Villarejo-Galende A; Atienza M; Palomar-Bonet M; Cantero JL; Perry G; Orive G; Ibañez B; Bueno H; Fuster V; Carro E
EBioMedicine; 2020 Jul; 57():102834. PubMed ID: 32586758
[TBL] [Abstract][Full Text] [Related]
3. Low levels of salivary lactoferrin may affect oral dysbiosis and contribute to Alzheimer's disease: A hypothesis.
Olsen I; Singhrao SK
Med Hypotheses; 2021 Jan; 146():110393. PubMed ID: 33229194
[TBL] [Abstract][Full Text] [Related]
4. Salivary Lactoferrin Expression in a Mouse Model of Alzheimer's Disease.
Antequera D; Moneo D; Carrero L; Bartolome F; Ferrer I; Proctor G; Carro E
Front Immunol; 2021; 12():749468. PubMed ID: 34659251
[TBL] [Abstract][Full Text] [Related]
5. Lactoferrin and Its Detection Methods: A Review.
Zhang Y; Lu C; Zhang J
Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444652
[TBL] [Abstract][Full Text] [Related]
6. Salivary Biomarkers for Alzheimer's Disease: A Systematic Review with Meta-Analysis.
Nijakowski K; Owecki W; Jankowski J; Surdacka A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256241
[TBL] [Abstract][Full Text] [Related]
7. Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota.
Li B; He Y; Ma J; Huang P; Du J; Cao L; Wang Y; Xiao Q; Tang H; Chen S
Alzheimers Dement; 2019 Oct; 15(10):1357-1366. PubMed ID: 31434623
[TBL] [Abstract][Full Text] [Related]
8. Porphyromonas gingivalis Outer Membrane Vesicles as the Major Driver of and Explanation for Neuropathogenesis, the Cholinergic Hypothesis, Iron Dyshomeostasis, and Salivary Lactoferrin in Alzheimer's Disease.
Nara PL; Sindelar D; Penn MS; Potempa J; Griffin WST
J Alzheimers Dis; 2021; 82(4):1417-1450. PubMed ID: 34275903
[TBL] [Abstract][Full Text] [Related]
9. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
[TBL] [Abstract][Full Text] [Related]
10. Reduced Salivary Lactoferrin Levels in Early-Onset Alzheimer's Disease.
Antequera D; Carrero L; Gonzalez-Sanchez M; Cantero JL; Orive G; Municio C; Carro E
Aging Dis; 2024 May; 15(3):945-947. PubMed ID: 37815910
[No Abstract] [Full Text] [Related]
11. Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin.
Carro E; Bartolomé F; Bermejo-Pareja F; Villarejo-Galende A; Molina JA; Ortiz P; Calero M; Rabano A; Cantero JL; Orive G
Alzheimers Dement (Amst); 2017; 8():131-138. PubMed ID: 28649597
[TBL] [Abstract][Full Text] [Related]
12. Lactoferrin of oral fluid is normal and in Alzheimer's disease: laboratory and diagnostic aspects (review of literature).
Bazarnyi VV; Sidenkova AP; Sosnin DY
Klin Lab Diagn; 2022 Apr; 67(4):207-212. PubMed ID: 35575393
[TBL] [Abstract][Full Text] [Related]
13. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease.
Kvartsberg H; Lashley T; Murray CE; Brinkmalm G; Cullen NC; Höglund K; Zetterberg H; Blennow K; Portelius E
Acta Neuropathol; 2019 Jan; 137(1):89-102. PubMed ID: 30244311
[TBL] [Abstract][Full Text] [Related]
14. Lactoferrin iron levels are reduced in saliva of patients with localized aggressive periodontitis.
Fine DH; Furgang D; Beydouin F
J Periodontol; 2002 Jun; 73(6):624-30. PubMed ID: 12083535
[TBL] [Abstract][Full Text] [Related]
15. Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer's Disease Patients.
Bartolomé F; Rosa L; Valenti P; Lopera F; Hernández-Gallego J; Cantero JL; Orive G; Carro E
Front Immunol; 2022; 13():878201. PubMed ID: 35547737
[TBL] [Abstract][Full Text] [Related]
16. A pilot study on the effect of lactoferrin on Alzheimer's disease pathological sequelae: Impact of the p-Akt/PTEN pathway.
Mohamed WA; Salama RM; Schaalan MF
Biomed Pharmacother; 2019 Mar; 111():714-723. PubMed ID: 30611996
[TBL] [Abstract][Full Text] [Related]
17. Deposition of lactoferrin in fibrillar-type senile plaques in the brains of transgenic mouse models of Alzheimer's disease.
Wang L; Sato H; Zhao S; Tooyama I
Neurosci Lett; 2010 Sep; 481(3):164-7. PubMed ID: 20599473
[TBL] [Abstract][Full Text] [Related]
18. Lactoferrin, a marker for periodontal disease.
Lourenço AG; Nakao C; Machado AA; Motta AC; Tonani L; Candido RC; Komesu MC
Curr HIV Res; 2013 Apr; 11(3):220-5. PubMed ID: 23432422
[TBL] [Abstract][Full Text] [Related]
19. Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for Alzheimer's disease.
Bartolome F; Orive G; Carro E
Alzheimers Dement (Amst); 2021; 13(1):e12173. PubMed ID: 33969170
[TBL] [Abstract][Full Text] [Related]
20. No association of salivary total tau concentration with Alzheimer's disease.
Ashton NJ; Ide M; Schöll M; Blennow K; Lovestone S; Hye A; Zetterberg H
Neurobiol Aging; 2018 Oct; 70():125-127. PubMed ID: 30007161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
